{"name":"Meiji Pharma","slug":"meiji","ticker":"4569.T","exchange":"TSE","domain":"meiji-seika-pharma.co.jp","description":"KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, and Uritos KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; and prescription medicines and quasi-drugs, and diagnostics business. In addition, the company offers subcontracted drug manufacturing services. It has development and commercialization ","hq":"Tokyo, Japan","founded":1924,"employees":"~1,998","ceo":"Daikichiro Kobayashi","sector":"Anti-Infectives / Generics","stockPrice":1404,"stockChange":31,"stockChangePercent":2.26,"marketCap":"$510M","metrics":{"revenue":798256248.4854243,"revenueGrowth":-17.2,"grossMargin":40.9,"rdSpend":0,"netIncome":21799881.387199998,"cash":95349190.77876183,"dividendYield":1.82,"peRatio":8.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Cefaclor patent cliff ($100.0M at risk)","drug":"Cefaclor","type":"patent_expiry","sentiment":"negative"},{"date":"2027-06-01","label":"Cefotiam patent cliff ($50.0M at risk)","drug":"Cefotiam","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Meiji Pharma Reports Q4 2023 Earnings","summary":"Meiji Pharma announced its Q4 2023 earnings, with revenue increasing 5% year-over-year.","drugName":"","sentiment":"neutral"},{"date":"2023-09-01","type":"deal","headline":"Meiji Pharma Partners with Cipla for Generic Medications","summary":"Meiji Pharma partnered with Cipla to develop and market generic medications in Japan.","drugName":"","sentiment":"positive"},{"date":"2023-06-15","type":"regulatory","headline":"Meiji Pharma Receives Approval for New Antibiotic","summary":"Meiji Pharma received regulatory approval for a new antibiotic in Japan.","drugName":"","sentiment":"positive"}],"realNews":[],"patents":[{"drugName":"Cefaclor","drugSlug":"cefaclor","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Cefotiam","drugSlug":"cefotiam","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"EU","annualRevenue":50000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Takeda Pharmaceutical","Eisai Co.","Mitsubishi Tanabe Pharma"],"therapeuticFocus":["Anti-infectives","Generics"],"financials":{"source":"yahoo_finance","revenue":822471337.0117999,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":822471337.0117999},{"period":"2024-03-31","value":755737651.3848},{"period":"2023-03-31","value":716146335.4779999},{"period":"2022-03-31","value":667235696.7276}],"grossProfit":376408334.79899997,"grossProfitHistory":[{"period":"2025-03-31","value":376408334.79899997},{"period":"2024-03-31","value":326416553.4392},{"period":"2023-03-31","value":317179422.7238},{"period":"2022-03-31","value":312589308.4874}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":79460820.5552,"operatingIncomeHistory":[{"period":"2025-03-31","value":79460820.5552},{"period":"2024-03-31","value":39414286.7076},{"period":"2023-03-31","value":32396343.4536},{"period":"2022-03-31","value":31662936.771199998}],"netIncome":57445975.1404,"netIncomeHistory":[{"period":"2025-03-31","value":57445975.1404},{"period":"2024-03-31","value":34615530.915},{"period":"2023-03-31","value":29861032.422199998},{"period":"2022-03-31","value":24859957.5448}],"eps":158.17,"epsHistory":[{"period":"2025-03-31","value":158.17},{"period":"2024-03-31","value":92.74},{"period":"2023-03-31","value":82.44},{"period":"2022-03-31","value":68.62}],"cash":94969842.8994,"cashHistory":[{"period":"2025-03-31","value":94969842.8994},{"period":"2024-03-31","value":87793837.86039999},{"period":"2023-03-31","value":122618010.3316},{"period":"2022-03-31","value":170668792.9716}],"totalAssets":1224144267.5252,"totalLiabilities":362492575.24759996,"totalDebt":179804764.1446,"equity":861651692.2775999,"operatingCashflow":22166584.7284,"operatingCashflowHistory":[{"period":"2025-03-31","value":22166584.7284},{"period":"2024-03-31","value":9793508.1986},{"period":"2023-03-31","value":12695522.5712},{"period":"2022-03-31","value":40122403.5044}],"capex":-39787312.5202,"capexHistory":[{"period":"2025-03-31","value":-39787312.5202},{"period":"2024-03-31","value":-39490156.3644},{"period":"2023-03-31","value":-59462843.517},{"period":"2022-03-31","value":-17007448.066}],"freeCashflow":-17620727.7918,"dividendsPaid":-19062251.270999998,"buybacks":null,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-06-30","revenue":null,"epsBasic":36.57,"netIncome":null,"rdExpense":null,"epsDiluted":36.57,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1404,"previousClose":1373,"fiftyTwoWeekHigh":1725,"fiftyTwoWeekLow":1359,"fiftyTwoWeekRange":"1359.0 - 1725.0","fiftyDayAverage":1618.62,"twoHundredDayAverage":1555.61,"beta":0,"enterpriseValue":564967802.6337615,"forwardPE":13.4,"priceToBook":0.58,"priceToSales":0.64,"enterpriseToRevenue":0.71,"enterpriseToEbitda":10.94,"pegRatio":0,"ebitda":51660912.595485486,"ebitdaMargin":6.5,"freeCashflow":0,"operatingCashflow":0,"totalDebt":150379988.31857255,"debtToEquity":16.7,"currentRatio":4.6,"returnOnAssets":1.1,"returnOnEquity":2.5,"analystRating":"4.0 - Underperform","recommendationKey":"underperform","numberOfAnalysts":1,"targetMeanPrice":1300,"targetHighPrice":1300,"targetLowPrice":1300,"dividendRate":25,"payoutRatio":0.32,"fiveYearAvgDividendYield":3.28,"exDividendDate":1790640000,"insiderHeldPercent":33,"institutionHeldPercent":23.4,"sharesOutstanding":57446295,"floatShares":36850120,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":162.29,"epsForward":105,"revenuePerShare":2197.77,"bookValue":2417.37,"officers":[{"age":58,"name":"Mr. Yutaka  Ogihara","title":"President, CEO & Chairman"},{"age":55,"name":"Mr. Yasuji  Kurose","title":"CFO, CSO, Managing Executive Officer, Director of Corporate Planning & Executive Director"},{"age":null,"name":"Junichi  Ishiyama","title":"Managing Executive Officer, CSO & Head of Drug Discovery Div."},{"age":null,"name":"Kiyoo  Uehara","title":"Managing Executive Officer, CHRO & General Affairs Manager"},{"age":65,"name":"Mr. Michiro  Onota","title":"Exe. Director, Mng. Corp. Off., CMO, Chairman of KYORIN Pharmaceutical Grp. Facilities Co., Ltd"},{"age":null,"name":"Takaaki  Kaji","title":"Senior Managing Executive Officer & Chief Business Development Officer"},{"age":null,"name":"Noriaki  Tamura","title":"Managing Executive Officer, Chief Commercial Officer & GM of Pharmaceutical Sales Division"},{"age":null,"name":"Mr. Kenichi  Nakamura","title":"Corporate Officer & President of KYORIN Pharmaceutical Group Facilities Co., Ltd."}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.kyorin-pharm.co.jp","phone":"81 3 6374 9700"}}